prikaz prve stranice dokumenta Lijekovi koji modificiraju tijek bolesti - multipla skleroza
  Download
PDF 2.05 MB
master's thesis
Lijekovi koji modificiraju tijek bolesti - multipla skleroza
Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. urn:nbn:hr:163:179317
Šalinović, Hrvoje
University of Zagreb
Faculty of Pharmacy and Biochemistry
Department of pharmacology

Cite this document

Šalinović, H. (2016). Lijekovi koji modificiraju tijek bolesti - multipla skleroza (Master's thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:179317

Šalinović, Hrvoje. "Lijekovi koji modificiraju tijek bolesti - multipla skleroza." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. https://urn.nsk.hr/urn:nbn:hr:163:179317

Šalinović, Hrvoje. "Lijekovi koji modificiraju tijek bolesti - multipla skleroza." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. https://urn.nsk.hr/urn:nbn:hr:163:179317

Šalinović, H. (2016). 'Lijekovi koji modificiraju tijek bolesti - multipla skleroza', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 19 April 2024, https://urn.nsk.hr/urn:nbn:hr:163:179317

Šalinović H. Lijekovi koji modificiraju tijek bolesti - multipla skleroza [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2016 [cited 2024 April 19] Available at: https://urn.nsk.hr/urn:nbn:hr:163:179317

H. Šalinović, "Lijekovi koji modificiraju tijek bolesti - multipla skleroza", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2016. Available at: https://urn.nsk.hr/urn:nbn:hr:163:179317

Please login to the repository to save this object to your list.
Metadata
TitleLijekovi koji modificiraju tijek bolesti - multipla skleroza
Title (english)Disease-modifying therapy - multiple sclerosis
AuthorHrvoje Šalinović
MentorPetra Turčić (mentor)
Committee memberPetra Turčić (predsjednik povjerenstva)
Committee memberLidija Bach-Rojecky (član povjerenstva)
Committee memberIvan Pepić (član povjerenstva)
GranterUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Department of pharmacology)
Zagreb
Defense date and country2016-05-18, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract
Multipla skleroza je idiopatska, pretežno autoimuna, kronična, upalna, demijelinizirajuća bolest SŽS-a s genetskim i okolišnim učincima. Karakterizirana je demijelinizacijom SŽS i oštećenjem aksona. Novija istraživanja potvrđuju i zahvaćenost sive tvari. MS uzrokuje teškoće i onesposobljavanje, smanjenu mobilnost, probleme s vidom, probleme s koordinacijom, kognitivnu disfunkciju, umor i bol. Trenutno je odobreno 13 terapija koje modificiraju tijek bolesti multiple skleroze s različitim stupnjevima učinkovitosti za smanjenje rizika od relapsa i očuvanje neurološke funkcije. Novi pristup liječenju uglavnom uključuje monoklonska protutijela koja specifično ciljaju mete. Potencijalne nove mete su razne molekule povezane sa trenutnim spoznajama o uzročnicima ove bolesti. Predviđamo postupni napredak prema uistinu personaliziranoj terapiji MS kako se genomika i srodne discipline budu koristile za objašnjavanje i bolje razumijevanje individualne heterogenosti bolesti.
Abstract (english)
Multiple sclerosis is an idiopathic, putatively autoimmune, a chronic inflammatory demyelinating central nervous system disease with genetic and environmental effects. MS is characterized by CNS demyelination and axonal damage. Recent research has also highlighted an underappreciated involvement of gray matter. Multiple sclerosis causes bothersome or disabling physical symptoms involving mobility problems, vision problems, problems with coordination, cognitive dysfunction, fatigue, and pain. Currently, there are 13 approved MS DMTs with varying degrees of efficacy for reducing relapse risk and preserving neurological function. New treatment approaches mostly include monoclonal antibodies that target specific sites. Potential new targets are various molecules linked with what´s currently considered to be a cause of the disease development. We foresee gradual steps toward truly personalized medicine for MS as large-scale genomics and related disciplines are applied to explain the individual heterogeneity.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:163:179317
Study programmeTitle: Pharmacy
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
RepositoryRepository of Faculty of Pharmacy and Biochemistry University of Zagreb
Created on2016-06-08 09:51:47

(©) Nacionalna i sveučilišna knjižnica u Zagrebu 2015. Sva prava pridržana. | Hrvatske bratske zajednice 4 p.p. 550, 10000 Zagreb, Hrvatska Tel. ++ 385 1 616-4040
OIB: 84838770814 | IBAN: HR66 2340 0091 1000 1008 1, Porezni broj (PDV identifikacijski broj) - VAT Number: HR84838770814
Prijava u repozitorij